SCHEMBL20973018

SCHEMBL20973018

Clc1ccc[c]c1-n1cccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.46
F2RL1 P55085 1/20 0.35
ALDH1A1 P00352 5/20 0.35
MAPT P10636 4/20 0.35
KDM4E B2RXH2 3/20 0.35
LMNA P02545 2/20 0.35
GAA P10253 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
G6PD P11413 1/20 0.35
MAPK1 P28482 2/20 0.35
NPC1 O15118 1/20 0.35
ADORA2A P29274 1/20 0.35
KCNN4 O15554 1/20 0.34
KCNA3 P22001 1/20 0.34
BRD4 O60885 1/20 0.32
DCTPP1 Q9H773 1/20 0.31
F2 P00734 1/20 0.31
PLAU P00749 1/20 0.31
KLKB1 P03952 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1586320 0.79 NOTUM (0.38) NOTUMALDH1A1MAPTKDM4ELMNA
SCHEMBL1586140 0.79 NOTUM (0.38) NOTUMF2RL1ALDH1A1MAPTKDM4E
SCHEMBL28553753 0.75 CYP1A2 (0.38) NOTUMALDH1A1MAPTKDM4EMEN1
SCHEMBL28549023 0.74 NOTUM (0.39) NOTUMALDH1A1MAPTKDM4ELMNA
SCHEMBL6119863 0.71 NOTUM (0.53) NOTUMF2RL1ALDH1A1MAPTKDM4E
SCHEMBL255914 0.69 MAPK1 (0.56) NOTUMALDH1A1MAPTKDM4ELMNA
SCHEMBL15402138 0.69 KMT2A (0.42) MAPTMEN1KMT2A
SCHEMBL15401526 0.69 NOTUM (0.31) NOTUM
SCHEMBL15401676 0.69 MAPT (0.34) NOTUMALDH1A1MAPTKDM4ELMNA
SCHEMBL15401924 0.69 L3MBTL1 (0.41) LMNAMEN1KMT2ANPC1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10550089-B2 Inhibitors of protease-activated receptor-2 HEPTARES THERAPEUTICS LIMITED (GB) 2020-02-04 US disclosed
US-20190144394-A1 INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 HEPTARES THERAPEUTICS LIMITED (GB) 2019-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10550089-B2 Inhibitors of protease-activated receptor-2 F2RL1, F2R, F2RL3 NOTUM 2049/4885F2RL1 1/4885ALDH1A1 3538/4885
US-20190144394-A1 INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 F2RL1, F2R, F2RL3 NOTUM 2049/4885F2RL1 1/4885ALDH1A1 3538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.